The SBIR/STTR programs, a vital source of non-dilutive funding for early-stage biotechs, remain on pause with no clear path to reauthorization. The logjam is due to a niche debate between a few members of Congress over foreign-funded company eligibility, stalling the entire program.
The Biosecure Act will establish two distinct lists of prohibited foreign biotech partners: a DoD-managed list (1260H) and a more subjective White House list. Companies receiving any federal funds must navigate both lists, adding significant compliance complexity for supply chains.
Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.
Despite DINE Therapeutics presenting strong DMD data that surpasses historical benchmarks, investor confidence is weak. The FDA's recent unpredictable decisions in rare disease have created a perception that regulatory pathways are no longer reliable, even with compelling clinical results.
Wave Life Sciences' drug candidate reduced fat while increasing lean mass, even though total body weight didn't decrease. This signals a strategic shift in obesity treatment, moving beyond simple weight reduction to focus on improving body composition and mitigating muscle loss, a key side effect of GLP-1s.
The National Defense Authorization Act (NDAA) has elevated biotech to a national security asset, alongside AI and quantum computing. This shift creates new funding opportunities through a dedicated Department of Defense (DOD) biotech office, distinct from traditional NIH grants.
The profile of a company prepared to go public has matured significantly. Unlike the 2020 boom where IND acceptance was a key milestone, today's IPO candidates typically need Phase 2 or even Phase 3 data, raising the quality bar but shrinking the potential pool of companies.
Unlike the NIH's science-driven approach, the Department of Defense's new biotech funding priorities will be reactive to geopolitical threats. The DOD will invest in areas where China is perceived to be advancing, such as synthetic biology and biologic data security, rather than funding basic research.
The NDAA introduces a "reverse CFIUS" policy requiring US investors to notify or seek permission before investing in foreign companies in sensitive sectors. While biotech is not yet included, this framework could be extended, significantly impacting global venture capital strategy.
While massive, oversubscribed follow-on financings for companies with positive data indicate renewed investor appetite, the true market recovery hinges on the IPO window reopening. Analysts remain deeply divided on whether 2026 will see a significant number of IPOs, suggesting a fragile recovery.
Data from J&J's Majestic 3 trial suggests its off-the-shelf bispecific combination could rival the efficacy of its own blockbuster CAR-T, Carvykti. This sets up an internal competition where a more accessible therapy could challenge a complex, personalized one in earlier lines of treatment.